| Cdc20 is an evolutionarily conserved WD40‑repeat protein that functions as the primary activator and substrate adaptor of the anaphase‑promoting complex/cyclosome (APC/C) during early mitosis, where it controls ubiquitin‑dependent degradation of key mitotic regulators and thereby coordinates metaphase–anaphase transition, chromosome segregation and mitotic exit. The protein contains an N‑terminal C box and a C‑terminal seven‑blade WD40 β‑propeller that together provide binding surfaces for APC/C, destruction motifs (D boxes and KEN boxes) in substrates such as securin and cyclin B, and regulatory factors including spindle checkpoint proteins, while additional sequence motifs such as the CRY box contribute to checkpoint signaling by modulating Cdc20’s association with inhibitory complexes. In metaphase, Cdc20 engages APC/C to form APC/C^Cdc20, an E3 ligase complex that works with E2 enzymes such as UbcH10 to polyubiquitylate securin and cyclin B, triggering separase activation and cohesin cleavage for sister chromatid separation and initiating cyclin B degradation to promote exit into anaphase and telophase; multiple mechanisms, including phosphorylation, spatial regulation and spindle assembly checkpoint (SAC) control, ensure that Cdc20‑APC/C activity is restrained until all chromosomes achieve proper bipolar attachment. The SAC converges on Cdc20 through assembly of the mitotic checkpoint complex (MCC), a heterotetramer containing MAD2, BUBR1, BUB3 and a Cdc20 molecule, which binds and inhibits APC/C^Cdc20 and prevents ubiquitination of securin and cyclin B while unattached kinetochores signal; structural and functional studies distinguish APC‑bound Cdc20 (CDC20^A) from MCC‑bound Cdc20 (CDC20^M), and clean dissection of Cdc20 motifs shows that the CRY box is critical for efficient MCC formation and checkpoint signaling, reinforcing the view that Cdc20 is the central integrator of kinetochore‑derived SAC signals into APC/C output. Beyond its canonical role at the metaphase–anaphase transition, Cdc20 has been shown to transcriptionally up‑regulate UbcH10 by physically interacting with an APC/C–CBP/p300 complex and recruiting it to the UbcH10 promoter in a cell‑cycle‑specific manner, demonstrating that Cdc20 can act as a transcriptional co‑regulator that co‑ordinates expression of its E2 partner with mitotic progression and potentially amplifies APC/C activity in proliferating cells. In cancer biology, Cdc20 is frequently overexpressed across a wide spectrum of solid tumors and hematologic malignancies, and high Cdc20 levels correlate with genomic instability and poor overall survival in many solid cancers, consistent with its role at the crossroads between chromosome segregation fidelity and cell‑cycle progression; deregulation of the Rb–E2F1 axis can up‑regulate Cdc20 and engage APC/C^Cdc20 transactivation, promoting chromosomal instability and aneuploidy. In gastric cancer and precursor lesions, immunohistochemical studies show that MAD2 and Cdc20 are most highly expressed in high‑grade dysplasia, with Cdc20 specifically staining the outer cells of cell‑in‑cell (entosis) structures and their overexpression associating with intestinal histology and favorable recurrence‑free and cancer‑specific survival, suggesting that Cdc20 levels and localization can serve both as markers of chromosomal instability–type tumors and as indicators of distinct clinicopathological behavior. Preclinical work using small‑molecule APC/C^Cdc20 inhibitors such as Apcin and proTAME demonstrates that blocking Cdc20 function induces mitotic arrest and apoptosis in lymphoma and multiple myeloma cells and synergizes with clinically relevant drugs, underscoring the therapeutic potential of targeting Cdc20–APC/C in malignancies that rely on high Cdc20 activity for unchecked cell division. |
